AnaptysBio (ANAB)
(Real Time Quote from BATS)
$23.71 USD
+0.28 (1.20%)
Updated Jun 10, 2024 12:14 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
AnaptysBio, Inc. [ANAB]
Reports for Purchase
Showing records 61 - 80 ( 156 total )
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2021 Abstract Titles for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Expectations Ahead of EADV Congress 2021; Reiterate Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
The FDA''s Accelerated Approval of JEMPERLI in dMMR Solid Tumors is Good News for AnaptysBio; Reiterate Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
AnaptysBio Reports 2Q21-Imsidolimab Development Plan on Track, Reiterate Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
The IL-36R Inhibitor, Spesolimab, Strengthens the Case for AnaptysBio?s Imsidolimab in Generalized Pustular Psoriasis
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: AnaptysBio, Inc.
Industry: Medical - Biomedical and Genetics
AnaptysBio: a Rare Value Play With a Clinical Catalyst Kicker; Initiate at Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M